

## **Sep. 08, 2023** 8:45 am-5:40 pm, PT

#### In-Person Workshop San Francisco Bay Area: Crowne Plaza Foster City

**Distribution and Disposition Studies for Biotherapeutics:** Multi-specific Antibodies, ADCs, Peptide Conjugates, Cell Therapies and Protein Degraders

Organizers: Ben-Quan Shen, Genentech; Mei Han, Merck Research Laboratories



**Victor Yip** Scientist 4, Genentech

Distribution and Disposition of Antibody-Drug Conjugates



Danielle Mandikian PhD, Sr. Principal Scientist, Genentech

Preclinical Determination of Biotherapeutic Distribution



Lisa O'Callaghan PhD, Principal Scientist,

Merck

Stability and Biotransformation of Biotherapeutic Peptides



**Mei Han\*** Principal Scientist, Amgen \*Current affiliation: Merck



Andy Boswell PhD, Distinguished Scientist, Genentech

Whole-body SPECT Imaging to Inform Biologic Disposition



**Greg Thurber** PhD, Associate Professor, Univ. of Michigan

Fundamentals of Effective Antibody Drug Conjugate Design



Huan-Chieh Chien PhD, Principal Scientist, Amgen

Protein Degraders: Insights into Distribution and Disposition from a ADME Perspective



Achala Punchi Hewage PhD, Senior Scientist, Amgen

Large Molecule Biotransformation in Support of Next Generation Biologics by Intact Mass Analysis Using Immunoaffinity Purification-Capillary Electrophoresis-Mass Spectrometry (IA-CE-MS) Workflow



Dale Miles MS, PhD, Distinguished Scientist and Director, Genentech

Disposition and Distribution of Adoptive Tcell Therapies: A Clinical Pharmacology Perspective

**Registration:** 

## **Major Sponsor**





https://www.pbss.org/aspx/eventInfo.aspx?eID=818



#### In-Person Workshop San Francisco Bay Area: Crowne Plaza Foster City

### **Distribution and Disposition Studies for Biotherapeutics:** Multi-specific Antibodies, ADCs, Peptide Conjugates, Cell Therapies and Protein Degraders

Organizers: Ben-Quan Shen, Genentech; Mei Han, Merck Research Laboratories

- Time (PT) Topic
- 8:45-9:00 am **1. PBSS Welcome and Overview of Distribution and Disposition of Larger Molecule Drugs** (Ben-Quan Shen, Genentech and Mei Han, Merck)
- 9:00-9:40 am **2. Distribution and Disposition of Antibody-Drug Conjugates** (Victor Yip, Scientist 4, Genentech)
- 9:40-10:20 am **3. Whole-body SPECT Imaging to Inform Biologic Disposition** (Andy Boswell, PhD, Distinguished Scientist, Genentech)
- 10:20-10:30 am Major Sponsor's Presentation (Applied BioMath)
- 10:30-10:50 am Break Period & Vendor Show
- 10:50-11:30am **4. Preclinical Determination of Biotherapeutic Distribution** (Danielle Mandikian, PhD, Sr. Principal Scientist, Genentech)
- 11:30-12:10pm 5. Fundamentals of Effective Antibody Drug Conjugate Design: More Than Small Molecule, Linker, and Antibody Combinations (Greg Thuber, PhD, Associate Professor of Chemical Engineering, Biomedical Engineering & Associate Chair of Graduate Education, Univ. of Michigan)
- 12:10-1:00pm Lunch, Sponsor (TBD)
- 1:00-1:40pm **6. Stability and Biotransformation of Biotherapeutic Peptides** (Lisa O'Callaghan, PhD, Principal Scientist, Merck)
- 1:40-2:20pm **7. Protein Degraders: Insights into Distribution and Disposition from a ADME Perspective** (Huan-Chieh Chien, PhD, Principal Scientist, Amgen, Inc.)
- 2:20-2:30pm Major Sponsor's Presentation (TBD)
- 2:30-2:50pm Break
- 2:50-3:30pm 8. Disposition and Distribution of Adoptive T-cell Therapies: A Clinical Pharmacology Perspective (Dale Miles, MS, PhD, Distinguished Scientist and Director, Genentech)
- 3:30-4:10pm 9. Large Molecule Biotransformation in Support of Next Generation Biologics by Intact Mass Analysis Using Immunoaffinity Purification-Capillary Electrophoresis-Mass Spectrometry (IA-CE-MS) Workflow (Mei Han\*, Principal Scientist, and Achala Punchi Hewage, PhD, Senior Scientist, Amgen, Inc.) \*Current affiliation: Merck
- 4:10-4:40pm Panel Discussion (All speakers)
- 4:40-5:40pm Happy Hour, Sponsor (TBD)
  - **Registration:**

https://www.pbss.org/aspx/eventInfo.aspx?eID=818



San Francisco Bay

# Sep. 08, 2023, Workshop Vendors

**Distribution and Disposition Studies for Biotherapeutics:** Multi-specific Antibodies, ADCs, Peptide Conjugates, Cell Therapies and Protein Degraders



















